Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up

Lucia Masarova, MD, Jorge E. Cortes, MD, Keyur P. Patel, MBBS, PhD, Susan M. O'Brien, MD, Graciela M. Nogueras González, MPH, Marina Y. Konopleva, MD PhD, Srdan Verstovsek, MD PhD, Guillermo Garcia-Manero, MD, Alessandra Ferrajoli, MD, Tapan M. Kadia, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Sara Emogene Dellasala, BS, Elias J. Jabbour, MD, Hagop M. Kantarjian, MD

Blood (2018) 132 (Supplement 1): 3011.

https://doi.org/10.1182/blood-2018-99-120155

Published: 2018

Journal Articles

Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting

Prajwal Chaitanya Boddu, MD, Hagop M. Kantarjian, MD, Abdul Rashid Shah, MD, Gautam Borthakur, MD, Srdan Verstovsek, MD PhD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Tapan Kadia, MD, Farhad Ravandi, MD, Nitin Jain, MD, Ahmad Alhuraiji, MD MRCP, Jan Burger, MD PhD, Steven M. Kornblau, MD, Sara Emogene Dellasala, BS, Sherry Pierce, BSN, BA, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 3073.

https://doi.org/10.1182/blood.V128.22.3073.3073

Published: 2016

Journal Articles

Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients

Blood (2016) 128 (22): 1220.

https://doi.org/10.1182/blood.V128.22.1220.1220

Published: 2016

Journal Articles

Clinical Characteristics of Philadelphia Positive T-Cell Lymphoid Leukemias - (de novo and blast phase CML)

Preetesh Jain, MBBS, MDDM, PhD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Rashmi Kanagal-Shamanna, MD, Keyur P. Patel, MD PhD, Sara Emogene DellaSala, BS, Sherry Pierce, BSN, BA, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Susan M. O'Brien, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 5436.

https://doi.org/10.1182/blood.V128.22.5436.5436

Published: 2016

Journal Articles

Does the Achievement of MR4.5 Improve the Outcome of Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Front Line Tyrosine Kinase Inhibitors (TKI)?

Lorenzo Falchi, MD, Hagop M. Kantarjian, MD, Xuemei Wang, MS, Elias Jabbour, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, Tapan Kadia, MD, Naveen Pemmaraju, MD, Alessandra Ferrajoli, MD, Naval Daver, MD, Sara Emogene Dellasala, BS, Sherry Pierce, BSN, BA, Srdan Verstovsek, MD PhD, Jorge E. Cortes

Blood (2015) 126 (23): 5158.

https://doi.org/10.1182/blood.V126.23.5158.5158

Published: 2015

Journal Articles

Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia

Ghayas C. Issa, MD, Hagop M. Kantarjian, MD, Elias Jabbour, Gautam Borthakur, MD, Srdan Verstovsek, MD, Sherry Pierce, BSN, BA, William Wierda, MD PhD, Alessandra Ferrajoli, MD, Guillermo Garcia-Manero, MD, Tapan Kadia, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Farhad Ravandi, MD, Sara Emogene DellaSala, BS, Jorge E. Cortes, MD

Blood (2015) 126 (23): 1577.

https://doi.org/10.1182/blood.V126.23.1577.1577

Published: 2015

NARROW

Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up

Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting

Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients

Clinical Characteristics of Philadelphia Positive T-Cell Lymphoid Leukemias - (de novo and blast phase CML)

Does the Achievement of MR4.5 Improve the Outcome of Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Front Line Tyrosine Kinase Inhibitors (TKI)?

Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up

Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting

Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients

Clinical Characteristics of Philadelphia Positive T-Cell Lymphoid Leukemias - (de novo and blast phase CML)

Does the Achievement of MR4.5 Improve the Outcome of Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Front Line Tyrosine Kinase Inhibitors (TKI)?

Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only